Report Feature
The future of the global hospital acquired disease testing market looks promising with opportunities in hospitals and intensive care units (ICUS). The global hospital acquired disease testing market is expected to grow with a CAGR of 14%-16% from 2020 to 2025. The major drivers for this market are increasing prevalence of hospital acquired infections, growing number of drug-resistant pathogens, and rising awareness among people of hospital acquired diseases.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global hospital acquired disease testing market report, please download the report brochure.
In this market, urinary tract infection is the fastest growing test type of hospital acquired disease testing, whereas hospitals and intensive care units (ICUs) is the fastest growing end user. Growth in various segments of the hospital acquired disease testing market are given below:
The study includes trends and forecast for the global hospital acquired disease testing market by test type, end user, and region as follows:
By Test Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals and Intensive Care Units (ICUs)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes and Maternity Centers
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
Spain
Italy
France
Asia Pacific
China
Japan
India
The Rest of the World
Brazil
Some of the hospital acquired disease testing companies profiled in this report include Diatherix Corp, Roche, Cantel Medical Corporation, Qiagen, and Cephid, bioMeriux.
Lucintel forecasts that urinary tract infection will remain the largest test type segment over the forecast period due to high prevalence of hospital acquired infections and increasingly popular techniques that are being used for preventing, diagnosing, & treating the hospital-associated infections, such as polymerise chain reaction (PCR), solid-phase hybridization, and microarrays.
Within this market, hospitals and intensive care units (ICUs) will remain the largest end user segment over the forecast period.
North America will remain the largest region over the forecast period due to increase in geriatric population and robust healthcare infrastructure in this region.
|
Features of the Global Hospital Acquired Disease Testing Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global hospital acquired disease testing market by test type (urinary tract infection, surgical site infection, pneumonia stents, blood stream infection, and methicillin-resistant staphylococcus aureus), end user (hospitals and intensive care units (ICUs), ambulatory surgical and diagnostic centers, and nursing homes and maternity centers), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global hospital acquired disease testing market? Q.5 What are the business risks and threats to the global hospital acquired disease testing market? Q.6 What are the emerging trends in this hospital acquired disease testing market and the reasons behind them? Q.7 What are some changing demands of customers in this hospital acquired disease testing market? Q.8 What are the new developments in this hospital acquired disease testing market? Which companies are leading these developments? Q.9 Who are the major players in this hospital acquired disease testing market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in this hospital acquired disease testing market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global hospital acquired disease testing market? |
Report Scope
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling |
| Market Segments | Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus), and End User (Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (Germany, United Kingdom, Spain, Italy, and France), Asia (China, Japan, and India), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
1. Executive Summary
4.1 Global Hospital Acquired Disease Testing Market by Region
4.2.1 Market by Test Type: Urinary Tract Infection, Surgical Site Infection,Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.2.2 Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.2.3 The United States Hospital Acquired Disease Testing Market
4.2.4 The Canadian Hospital Acquired Disease Testing Market
4.2.5 The Mexican Hospital Acquired Disease Testing Market
4.3.1 Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.3.2 Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.3.3 The German Hospital Acquired Disease Testing Market
4.3.4 The United Kingdom Hospital Acquired Disease Testing Market
4.3.5 The Spain Hospital Acquired Disease Testing Market
4.3.6 The Italy Hospital Acquired Disease Testing Market
4.3.7 The French Hospital Acquired Disease Testing Market
4.4.1 Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.4.2 Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.4.3 The Chinese Hospital Acquired Disease Testing Market
4.4.4 The Indian Hospital Acquired Disease Testing Market
4.4.5 The Japanese Hospital Acquired Disease Testing Market
4.5.1 Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.5.2 Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.5.3 Brazilian Hospital Acquired Disease Testing Market
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
